Innovating.works Conecta tu I+D

Showing 1 to 20 of 73 results

NUCLEAR: METABOLIC REGULATION OF GENOME FUNCTION AND CELL IDENTITY ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un HORIZON EUROPE: HORIZON-MSCA-2023-DN-01 NUCLEAR aims at educating future experts that can drive the emerging field of Metabolic Regulation of Genome Function and Cell Identity rele...
2024-06-25 - 2029-02-28 | Financiado

DEFINITIVE: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 HER2+ breast cancer affects around 390.000 women annually worldwide (i.e. 3 patients every 4 minutes). Over the last decade, polychemotherap...
2023-12-11 - 2028-11-30 | Financiado

T-BAP: Targeting the Polycomb Machinery in BAP1-related Pathologies ISTITUTO EUROPEO DI ONCOLOGIA SRL tramitó un HORIZON EUROPE: ERC-2022-POC2 BAP1-related mutations are common genetic lesions of several cancers and neurodevelopmental disorders (NDDs). BAP1 is a deubiquitinase that...
2023-12-06 - 2025-06-30 | Financiado

iBeCHANGE: IBeCHANGE - ADDRESSING PSYCHOSOCIAL AND LIFESTYLE RISK FACTORS TO PROMOTE PRIMARY CANCER PREVENTION:... ISTITUTO EUROPEO DI ONCOLOGIA SRL tramitó un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 "Europe’s Beating Cancer Plan set has ambitious goals addressing key behavioral risk factors for cancer development, such as tobacco (target...
2023-12-01 - 2028-11-30 | Financiado

SHAPINCELLFATE: Impact of cell shapes on cell behaviour and fate ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un HORIZON EUROPE: ERC-2022-SYG Cells are often depicted as irregular spherical objects - the shape they adopt in suspension. However, the packed environment of tissues alt...
2023-03-06 - 2029-03-31 | Financiado

I3LUNG: Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherap... ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un HORIZON EUROPE: HORIZON-HLTH-2021-CARE-05 Immunotherapy (IO) is the new standard of care for many patients with advanced Non-Small Cell Lung Cancer (aNSCLC), yet only around 30-50% o...
2022-05-23 - 2027-05-31 | Financiado

EuCARE: European Cohorts of Patients and Schools to Advance Response to Epidemics ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 The EuCARE project gathers a comprehensive multidisciplinary team of clinicians, virologists, epidemiologists, statisticians and top experts...
2021-11-15 - 2026-10-13 | Financiado

OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado

EGFRtoMITO: EGFR signalling talks to mitochondria through contact sites ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: ERC-2020-COG The integration of distinct internalization routes is crucial to determine the fate of plasma membrane (PM) receptors and the output of thei...
2021-06-14 - 2027-06-30 | Financiado

CARDIOCARE: AN INTERDISCIPLINARY APPROACH FOR THE MANAGEMENT OF THE ELDERLY MULTIMORBID PATIENT WITH BREAST CANC... ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-SC1-BHC-2018-2020 More than 50% of the newly diagnosed breast cancer patients are elderly and particularly susceptible to cardiotoxicity of cancer treatment d...
2021-01-22 - 2025-06-30 | Financiado

DUPDOWN: Deacetylase inhibitors for autism spectrum disorders an integrated preclinical validation pipeline... ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: ERC-2019-PoC ASD is a very prevalent neurodevelopmental condition affecting more than 1% individuals, and represents a major unmet medical need since no...
2020-06-10 - 2022-12-31 | Financiado

oncNGS: NGS diagnostics in 21st century oncology the best for all at all times ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-SC1-BHC-2018-2020 OncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumo...
2019-12-13 - 2026-04-30 | Financiado

METROFOOD-PP: METROFOOD RI Preparatory Phase Project ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-INFRADEV-2018-2020 METROFOOD-RI – Infrastructure for Promoting Metrology in Food and Nutrition - is a pan-European Research Infrastructure (RI) aimed to promot...
2019-11-20 - 2022-05-31 | Financiado

ENHPATHY: Molecular basis of human enhanceropathies ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-MSCA-ITN-2019 Mutations within coding genes have traditionally been considered the major genetic cause of human disease. However, it is becoming increasin...
2019-08-09 - 2024-02-29 | Financiado

EPIC-XS: European Proteomics Infrastructure Consortium providing Access ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-INFRAIA-2018-2020 In life sciences research, proteomics technologies promise to be even more revolutionary than genomics for understanding the molecular mecha...
2018-12-03 - 2023-06-30 | Financiado

ChromDesign: Chromatin architecture and Design ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-MSCA-ITN-2018 ChromDesign is an innovative and interdisciplinary network of 10 European academic and private institutions that will characterize how 3D ch...
2018-08-20 - 2023-02-28 | Financiado

ATLAS: AuTonomous intraLuminAl Surgery ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-MSCA-ITN-2018 In modern surgery body lumens increasingly serve as access route to deeply located anatomic regions. Navigation through narrow and mostly fr...
2018-08-17 - 2023-03-31 | Financiado

EDIReX: EurOPDX Distributed Infrastructure for Research on patient derived cancer Xenografts ISTITUTO EUROPEO DI ONCOLOGIA SRL participó en un H2020: H2020-INFRAIA-2016-2017 Counteracting high attrition rates in oncology drug development and providing optimal therapeutic management of cancer patients require prec...
2017-12-08 - 2022-07-31 | Financiado

ITHACA: Immuno targeting of human AML quiescent cells by a novel phage display approach. ISTITUTO EUROPEO DI ONCOLOGIA SRL tramitó un H2020: ERC-2017-PoC One main objective of our ERC Advanced Grant project (InMec, No 341131) was to determine how cancer stem cells (CSCs) contribute to tumour g...
2017-10-31 - 2019-06-30 | Financiado